NAD+ IV therapy is one of the fastest-growing add-ons in aesthetic and wellness clinics in 2026, and it's also one of the easiest ways to get flagged in a state board audit if the oversight structure is thin. This guide ranks the medical director service models that actually hold up for NAD+ clinics, not just the ones that look cheapest on a sales page.
- Dedicated medical director oversight is the strongest match for best medical director services for NAD+ IV therapy clinics in 2026 — Buy.
- Collaborating physician agreements matter more for NAD+ than for Botox because NAD+ is typically a prescription-compounded infusion.
- Generic telehealth sign-off services that never review a chart are the weakest option for NAD+ clinics — Skip.
- Good faith exam packages and chart review are separate services; NAD+ clinics that skip one usually get flagged on the other.
Why this matters
NAD+ IV therapy sits in a gray zone that most medspa compliance checklists don't cover well. It's infused, not injected under the skin like Botox or filler, it's frequently compounded, and in many states that combination triggers physician-level oversight requirements that a standard collaborating agreement written for injectables doesn't fully address.
A clinic that adds NAD+ to the menu without updating its medical director for NAD+ IV therapy clinics coverage is running a new service line under old paperwork. That's the gap state boards look for first, because it's the easiest to prove.
How this list is ranked
Each service model below is scored on three things that matter specifically for NAD+ programs: whether it addresses prescription-compounded infusion oversight, whether it includes documented chart review (not just a signature), and whether it scales past a single location without a rewrite. Models that only cover injectable-style supervision and skip infusion-specific review get marked down, regardless of price.
The ranked list
1. Dedicated medical director oversight for NAD+ programs
The foundation pick, and the one most NAD+ clinics underbuy. A dedicated medical director reviews the standing orders for the infusion protocol itself, not just the injectable menu, which matters because NAD+ dosing and drip rates vary by patient in a way Botox units don't.
US Medical Directors structures this as an ongoing relationship rather than a one-time sign-off, with oversight tied to the specific service being offered. For a clinic running NAD+ as a core offering rather than an occasional add-on, this is the coverage that survives an inspection. Verdict: Buy.
2. Collaborating physician agreements built for NAD+ IV therapy
The compliance backbone for any clinic where a nurse practitioner or RN is administering NAD+ under delegated authority. A collaborating physician agreement written for aesthetic injectables generally doesn't name infusion therapy, prescription compounding, or IV administration explicitly, and that omission is exactly what an auditor circles.
Collaborating physician agreements for medspas adding NAD+ IV therapy exist for this reason — the agreement gets updated to name the service before it launches, not after a complaint. Verdict: Buy.
3. Good faith exam packages for NAD+ patients
The exam layer that most clinics assume their Botox provider already covers. It doesn't, in most states, because a good faith exam tied to an injectable consult isn't automatically valid for a separate infusion service with its own contraindications — cardiac history, kidney function, and medication interactions all matter more for an IV drip than for a syringe.
Good faith exam providers for aesthetic nurses that structure exams per service line, rather than one blanket exam per patient, close this gap. Verdict: Buy.
4. Chart review for multi-location NAD+ operators
The audit trail. A single medical director can sign off on protocols once and never look at a chart again — that's not oversight, that's a rubber stamp, and boards in 2026 are increasingly asking to see the review history, not just the agreement. For a clinic running NAD+ at two or more locations, chart review needs a workflow, not a spot check.
This model costs more than a bare signature, and it's worth it the moment a clinic has more than one site or more than one provider touching NAD+ orders. Verdict: Consider.
5. Bulk or group pricing for medspa groups scaling NAD+
The scale play. Medspa groups adding NAD+ across three, five, or more locations don't need three, five, or more separate contracts negotiated one at a time — that's how coverage gaps happen between locations. Group pricing structures bundle medical director oversight, good faith exams, and chart review under one negotiated rate across all sites.
This only makes sense once a group has committed to NAD+ as a standard menu item, not a pilot at one location. Verdict: Consider.
6. Generic telehealth sign-off with no chart review
The shortcut that isn't. Some services sell a fast, cheap physician signature with no ongoing review of patient charts, no infusion-specific standing orders, and no documented oversight of the NAD+ protocol itself. It's the least expensive option on paper and the most exposed option in an actual inspection.
If the service can't describe how it reviews NAD+ patient charts specifically, it isn't oversight — it's paperwork. Verdict: Skip.
“If your medical director never opens your NAD+ charts, you don’t have oversight — you have a signature.”
Comparison table
| Service model | Covers infusion protocol | Documented chart review | Scales multi-location | Verdict |
|---|---|---|---|---|
| Dedicated medical director oversight | Yes | Yes | Yes | Buy |
| Collaborating physician agreement (NAD+-specific) | Yes | Partial | Yes | Buy |
| Good faith exam package (per-service) | Yes | N/A | Yes | Buy |
| Chart review workflow | N/A | Yes | Yes | Consider |
| Bulk/group pricing | Depends on contract | Depends on contract | Yes | Consider |
| Generic telehealth sign-off | No | No | No | Skip |
Get NAD+ oversight structured right
Coverage built around infusion therapy, not repurposed injectable paperwork.
Where to source coverage
- Match the agreement to the service, not the clinic type. A general medspa collaborating agreement rarely names NAD+ or infusion therapy specifically — ask to see the exact language before signing.
- Confirm the good faith exam is per service line. One exam covering Botox does not automatically extend to NAD+ IV therapy in most states.
- Ask how chart review is documented. "We review charts" is not an answer; a dated review log for NAD+ patients is.
FAQ
What is the best medical director service for a NAD+ IV therapy clinic in 2026?
Dedicated medical director oversight that names NAD+ infusion therapy specifically in the standing orders is the strongest option in 2026. A generic injectables-only agreement usually doesn’t cover the infusion protocol.
Does NAD+ IV therapy need a different collaborating physician agreement than Botox?
Yes, in most cases. NAD+ is typically a prescription-compounded infusion with different contraindications than injectables, so the agreement needs to name the service explicitly.
Do NAD+ patients need a separate good faith exam?
In most states, yes — a good faith exam tied to an injectable consult doesn’t automatically cover infusion therapy. Cardiac and kidney history matter more for an IV drip.
How much does medical director oversight cost for a NAD+ clinic?
Costs vary by state, service volume, and whether the clinic needs a single provider or multi-location coverage; group pricing can reduce per-location cost for medspa groups adding NAD+ across sites.
Can one medical director cover NAD+ across multiple clinic locations?
Yes, but the agreement and chart review workflow need to be built for multiple sites from the start rather than added location by location.
Is a telehealth-only physician sign-off enough for NAD+ compliance?
No. A sign-off with no documented chart review of NAD+ patients doesn’t meet the oversight standard most state boards look for during inspection.
What’s the difference between chart review and a good faith exam for NAD+?
A good faith exam happens before treatment starts; chart review is the ongoing documentation showing a physician reviewed patient records afterward. NAD+ clinics need both.
Who needs a collaborating physician for NAD+ IV therapy?
Nurse practitioners and RNs administering NAD+ under delegated authority typically need a collaborating physician agreement that names infusion therapy specifically.
One last thing
The detail most clinics miss isn't the medical director agreement — it's that NAD+ is almost always a compounded prescription product, which means the oversight standard is closer to a prescribing relationship than an injectable supervision relationship. Clinics that treat it like "just another add-on" on the same paperwork as Botox are the ones that get asked hard questions first in 2026.
Related guides
- How to add NAD+ IV therapy to your medspa's service menu compliantly
- Best group pricing for medical director services
